Despite the success of immune checkpoint inhibitors in certain cancers, many late-stage solid tumors remain “immune cold,” characterized by low T-cell infiltration, dense extracellular matrix (ECM), stromal and vascular barriers, and poor responses to systemic immunotherapy.
